The FDA has announced that it is proposing to formally exclude semaglutide (Ozempic, Wegovy; Novo Nordisk), tirzepatide (Mounjaro, Zepbound; Eli Lilly and Company), and liraglutide (Victoza, Saxenda; Novo Nordisk) from the 503B outsourcing facility bulk drug substances (bulks) list - the regulatory mechanism that governs which active pharmaceutical ingredients large-scale compounding operations may use. Read more at Pharmacy Times >